Federal Register #2026-16449

Licensing Opportunity: CRISPR-Engineered Cancer Cell Line and Inducible IL-12 Platform for Immunotherapy Research

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health, offers licenses for two innovative biomedical research tools targeting oncology and immunotherapy research: - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Technology Transfer Center - OEMs/Vendors: - National Cancer Institute (NCI) (government-owned inventions) - Products/Technologies Offered: - MC38 B2m Knockout Murine Colon Cancer Cell Line (Part Number: E12320260) - CRISPR/Cas9-engineered cell line modeling tumor resistance to PD-1/PD-L1 checkpoint blockade - Research tool for studying immune escape, checkpoint-refractory tumors, and immunotherapy resistance - Drug-Regulatable, Inducible Membrane-Bound Interleukin 12 (DRIM-IL-12) (Part Number: E2172023) - Drug-responsive IL-12 cytokine platform for adoptive cell therapy (CAR, TCR, TILs) - Enhances anti-tumor efficacy and safety in engineered T-cell therapies - Unique/Notable Requirements: - This is a licensing opportunity for government-owned inventions, not a procurement of physical goods - No specific purchase quantities; licenses are for research and development use - Technologies are designed for advanced cancer immunotherapy research, including modeling resistance and improving cell therapy safety/efficacy

Description

The National Cancer Institute (NCI) is offering a license for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line. This cell line models tumor resistance to PD-1/PD-L1 checkpoint blockade caused by loss of MHC-I antigen presentation, providing a research tool to study checkpoint-refractory tumors. It enables evaluation of alternative or combination immunotherapy strategies for cancers that evade conventional T-cell-mediated recognition. The model is based on the MC38 colon cancer model and is useful for mechanistic studies of tumor immune escape and immunotherapy resistance.

View original listing